References
- Gladman D. D. Psoriatic arthritis. Dermatol Ther 2004; 17: 350–63
- Ruderman E. M. Evaluation and management of psoriatic arthritis: The role of biologic therapy. J Am Acad Dermatol 2003; 49: S125–32
- Biondi Oriente C., Scarpa R., Pucino A., Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co‐operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69–71
- Leonard D. G., O'Duffy J. D., Rogers R. S. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978; 53: 511–8
- Scarpa R., Oriente P., Pucino A., Torella M., Vignone L., Riccio A., et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23: 246–50
- Shbeeb M., Uramoto K. M., Gibson L. E., O'Fallon W. M., Gabriel S. E. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 1247–50
- Gladman D. D., Shuckett R., Russell M. L., Thorne J. C., Schachter R. K. Psoriatic arthritis (PSA) – an analysis of 220 patients. Q J Med 1987; 62: 127–41
- Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460–8
- Harrison B. J., Silman A. J., Barrett E. M., Scott D. G., Symmons D. P. Presence of psoriasis does not influence the presentation or short‐term outcome of patients with early inflammatory polyarthritis. J Rheumatol 1997; 24: 1744–9
- Husted J. A., Gladman D. D., Farewell V. T., Cook R. J. Health‐related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001; 45: 151–8
- Sokoll K. B., Helliwell P. S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001; 28: 1842–6
- Husted J. A., Gladman D. D., Long J. A., Farewell V. T. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995; 13: 439–43
- Brockbank J., Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002; 62: 2447–57
- Mease P. J. Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61: 298–304
- Mehlis S. L., Gordon K. B. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003; 49: S44–50
- Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356: 385–90
- Mease P. J., Kivitz A. J., Burch F. X., Siegel E. L., Cohen S. B., Ory P., et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–72
- Singri P., West D. P., Gordon K. B. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol 2002; 138: 657–63
- Enbrel® (etanercept) Full Prescribing Information. Amgen Inc. and Wyeth‐Ayerst Pharmaceuticals, Thousand Oaks, CA 2006
- Langley R. G., Ellis C. N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563–9
- Shikiar R., Bresnahan B. W., Stone S. P., Thompson C., Koo J., Revicki D. A. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes 2003; 1: 53
- Cheah S. Y., Clark C., Goldberg L., Li Wan Po A., Phillips R. Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. J Clin Pharm Ther 1996; 21: 297–316
- Carlin C. S., Feldman S. R., Krueger J. G., Menter A., Krueger G. G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859–66
- Gottlieb A. B., Chaudhari U., Baker D. G., Perate M., Dooley L. T. The National Psoriasis Foundation Psoriasis Score (NPF‐PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A comparison. J Drugs Dermatol 2003; 2: 260–6
- Gottlieb A. B., Matheson R. T., Lowe N., Krueger G. G., Kang S., Goffe B. S., et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–32, discussion 1632
- Leonardi C. L., Powers J. L., Matheson R. T., Goffe B. S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22